

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Form 4

August 26, 2010

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
GOMEZ JOHN

(Last) (First) (Middle)

222 MERCHANDISE MART
PLAZA, SUITE 2024

(Street)

CHICAGO, IL 60654

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. [MDRX]

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2010

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
X Officer (give title below) ___ Other (specify below)
Pre, Product Strategy & Dev

6. Individual or Joint/Group Filing(Check Applicable Line)
X Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Amount or Price		
Common Stock	08/24/2010		A		76,500	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. - Form 4

- (2) Received pursuant to the Merger Agreement in exchange for a stock option to acquire 30,000 shares of Eclipsys Corporation common stock for \$13.26 per share.
- (3) Received pursuant to the Merger Agreement in exchange for a stock option to acquire 50,000 shares of Eclipsys Corporation common stock for \$11.95 per share.
- (4) Received pursuant to the Merger Agreement in exchange for a stock option to acquire 120,000 shares of Eclipsys Corporation common stock for \$13.35 per share.
- (5) Received pursuant to the Merger Agreement in exchange for a stock option to acquire 140,000 shares of Eclipsys Corporation common stock for \$19.70 per share.
- (6) The option may be exercised only to the extent vested. The option is vested with respect to 60.4167% of the underlying shares, and vests with respect to the remaining 39.5833% in 19 equal monthly installments over the nineteen-month period ending March 4, 2012.
- (7) Received pursuant to the Merger Agreement in exchange for a stock option to acquire 35,000 shares of Eclipsys Corporation common stock for \$22.07 per share.
- (8) The option may be exercised only to the extent vested. The option is vested with respect to 35.4167% of the underlying shares, and vests with respect to the remaining 64.5833% in 31 equal monthly installments over the thirty-one-month period ending February 27, 2013.
- (9) Received pursuant to the Merger Agreement in exchange for a stock option to acquire 105,000 shares of Eclipsys Corporation common stock for \$7.97 per share.
- (10) Each Performance Stock Unit ("PSU") represents a contingent right to receive a number of shares of Allscripts common stock ranging from zero to 2.7, depending upon Eclipsys' total shareholder return ("TSR") compared to the TSRs of a group of pre-selected companies in the healthcare technology and software industries over a performance period commencing on March 15, 2010 ending on August 24, 2010, the effective date of the merger.
- (11) Assumes Eclipsys' TSR was at the 50th percentile of the comparison group. Actual payout for PSUs can range from 0% to 270% of the amount shown depending upon relative TSRs for the performance period.
- (12) Received pursuant to the Merger Agreement in exchange for an identical number of performance share units payable in Eclipsys Corporation common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.